Slide Deck

I. Executive Summary

AFLAC Inc. (AFL) stands at a critical strategic juncture, operating as a distinct anomaly within the global insurance sector: a U.S.-domiciled corporation that derives the overwhelming majority of its economic value—approximately 70% of pretax adjusted earnings and 77% of assets—from the Japanese market.¹ For decades, this geographic arbitrage allowed AFLAC to exploit a lucrative niche in cancer insurance (“third sector” products) within a protected Japanese regulatory environment, utilizing the prodigious cash flows generated in Yen to fund reliable dividends and share repurchases in U.S. Dollars. However, a rigorous forensic analysis of the company’s financial performance, market dynamics, and risk profile through late 2025 suggests that the historical “moat” protecting this arbitrage is undergoing structural erosion.

The core investment thesis for AFLAC has traditionally rested on three pillars: the unmatched brand equity of the “Aflac Duck,” a fortress balance sheet, and a dominant market share in Japanese supplemental health insurance. The evidence accumulated through the third quarter of 2025 challenges the durability of these pillars. While the brand remains potent, particularly in the United States, the company faces existential headwinds in Japan driven by severe demographic contraction, intense competition from domestic giants like Nippon Life, and a fragile distribution ecosystem rocked by recurring scandals at its primary partner, Japan Post Holdings.

Financially, AFLAC appears robust on the surface, reporting a Return on Equity (ROE) of approximately 15.6% ² and net earnings of $5.4 billion for the full year 2024.¹ Yet, a decomposition of these returns reveals a heavy reliance on “financial engineering”—specifically, the aggressive repurchase of shares (over $1 billion in Q3 2025 alone ³)—to manufacture Earnings Per Share (EPS) growth in the face of stagnant or declining organic revenues. In U.S. dollar terms, revenues have faced pressure from a historically weak Yen, forcing management to navigate complex hedging strategies that protect capital ratios but do not necessarily shield reported earnings from volatility.

Furthermore, the company’s pivot toward “asset formation” products in Japan, exemplified by the launch of Tsumitasu in 2024, represents a strategic concession. By moving away from high-margin, pure-protection cancer policies toward lower-margin, savings-oriented products to capture younger demographics, AFLAC risks diluting the superior profitability that has historically commanded a premium valuation. Simultaneously, the investment portfolio has migrated further out on the risk curve, with significant allocations to middle-market private credit and transitional commercial real estate loans, sectors currently exhibiting rising delinquency rates.⁴

This report provides a critical, evidence-based assessment of AFLAC’s long-term viability. It posits that while AFLAC is unlikely to face imminent financial distress due to its strong capital position, it has transitioned from a “growth compounder” to a “managed liquidation” vehicle, extracting value from a mature Japanese book of business to return capital to shareholders. The analysis that follows details the mechanics of this transition, the fragility of the Japanese distribution channels, the execution risks in the U.S. group benefits expansion, and the hidden leverage within the investment portfolio.

II. The Japanese Core: Anatomy of a Decaying Monopoly

To understand AFLAC is to understand the Japanese insurance market. Despite its headquarters in Columbus, Georgia, AFLAC is operationally a Japanese financial institution. The health of the Japanese subsidiary is the single most critical determinant of the company’s intrinsic value.

2.1 The Erosion of the “Third Sector” Moat

Historically, AFLAC enjoyed a “regulatory moat.” When it entered Japan in 1974, the Ministry of Finance granted it a license to sell cancer insurance (classified as “third sector” products), effectively barring domestic giants like Nippon Life and Dai-ichi Life from this niche to protect the foreign entrant. This allowed AFLAC to build a massive database of cancer actuarial data, enabling precise underwriting that competitors could not match.

However, deregulation in the early 2000s opened the floodgates. Today, the Japanese third-sector market is a “red ocean” of competition. While AFLAC remains the leader with over 22 million policies in force ⁶, its market share of new sales is under siege. Competitors are leveraging broader balance sheets to offer bundled products (life + medical + cancer) that AFLAC, as a niche player, struggles to match. The data suggests that AFLAC’s “moat” is no longer based on exclusivity or data superiority, but merely on the inertia of its existing massive book of business.

2.2 The Japan Post Scandal: A Structural Fracture in Distribution

A critical vulnerability in AFLAC’s business model is its dependence on third-party distribution, specifically the alliance with Japan Post Holdings. This partnership, which provides access to over 20,000 postal outlets nationwide ⁷, was once the jewel in AFLAC’s crown. It has now become a liability of reputational and operational risk.

The 2019 Precedent:

In 2019, revelations surfaced that Japan Post employees had engaged in predatory sales tactics, such as double-charging premiums and selling unnecessary policies to the elderly to meet aggressive quotas.8 This resulted in a government-ordered suspension of insurance sales, causing AFLAC’s sales through this channel to plummet.

The 2024-2025 Recurrence:

Disturbingly, the governance issues at Japan Post appear systemic rather than episodic. In 2024 and extending into 2025, new scandals emerged involving the improper handling of sensitive customer data. Reports indicate that Japan Post Insurance improperly accessed and utilized non-public financial information of approximately 10 million clients from its banking affiliate, Japan Post Bank, to solicit insurance products.9

The implications for AFLAC are profound:

1. Channel Volatility: The recurrence of misconduct has led to renewed regulatory scrutiny and “self-restraint” in sales activities, dampening volume from what should be AFLAC’s most powerful distribution lever.
2. Reputational Contagion: While AFLAC itself was not the primary perpetrator, its brand is inextricably linked to Japan Post in the eyes of millions of rural Japanese consumers. The “trust” essential for selling intangible promises like insurance is being eroded.
3. Strategic Paralysis: AFLAC cannot easily divorce itself from Japan Post without sacrificing a massive portion of its distribution footprint. It is held hostage by the governance failures of its partner.

2.3 The “Tsumitasu” Pivot: Revenue vs. Margin

In response to the saturation of the cancer insurance market and the aging population, AFLAC Japan launched Tsumitasu in June 2024.⁶ This product is a hybrid: a nursing care insurance product with an asset formation (savings) component, designed to appeal to younger consumers worried about the solvency of the Japanese state pension system.

The Economic Trade-off:

Management touts the success of Tsumitasu in driving a sales recovery—reporting a 12.6% increase in sales in Q1 2025 11 and continued momentum through Q3 2025.3 However, a critical analysis of the product economics reveals a less rosy picture.

• Lower Margins: Asset accumulation products (“First Sector” characteristics) inherently carry lower profit margins than pure risk-protection products (“Third Sector” cancer/medical). The insurer must essentially act as a money manager, offering a competitive yield to the consumer, which squeezes the spread available for profit.
• Capital Intensity: Savings products require higher capital reserves compared to annual renewable health policies, potentially depressing ROE.
• The “Cannibalization” Effect: There is a risk that Tsumitasu sales are merely replacing higher-margin cancer sales rather than being purely additive. While Q3 2025 data shows cancer insurance sales (Miraito) also growing ³, the long-term trend of mix-shift toward savings products creates a structural headwind for AFLAC’s famously high Japan margins (which exceeded 30% pretax in previous years).

2.4 The Launch of “Miraito”: Defending the Core

To counter the commoditization of cancer insurance, AFLAC launched Miraito in March 2025.³ This product offers “comprehensive” coverage, including payments for expensive, advanced medical treatments and outpatient care, reflecting the shift in cancer treatment protocols in Japan.

• Performance: Early data is positive, with Miraito driving a 42% increase in cancer insurance sales in Q3 2025.¹²
• The “Churn” Factor: A significant portion of these “new” sales are likely conversions of existing policyholders updating their old coverage. While this updates the book and resets the persistency clock, it does not necessarily expand the customer base in a shrinking population. It is a defensive maneuver to prevent policyholders from defecting to competitors like Nippon Life, rather than an offensive conquest of greenfield market share.

III. The U.S. Segment: Struggling for Scale in a Crowded Market

If Japan is the “cash cow,” Aflac U.S. is the putative “star” meant to deliver growth. However, the evidence suggests the U.S. operation is struggling to break out of a low-growth trajectory amidst fierce competition.

3.1 Worksite Saturation and the Gig Economy

AFLAC’s traditional U.S. model—individual agents selling supplemental policies to employees at small businesses via payroll deduction—is facing secular headwinds.

• Labor Market Shifts: The rise of the gig economy and remote work has fragmented the traditional worksite. Agents can no longer physically visit a breakroom to sign up employees.
• Digital Disintermediation: Younger workers prefer enrolling in benefits online without agent intervention. While AFLAC has invested in digital platforms, it trails “insurtech” natives and integrated carriers who offer seamless digital enrollment.
• Sales Stagnation: In Q3 2025, U.S. sales grew only 2.8% to $390 million.¹³ Adjusted for inflation, this represents stagnant or declining real volume. This lackluster growth persists despite heavy marketing spend and brand ubiquity.

3.2 The Group Benefits Pivot: Buying Relevance

Recognizing the limits of the individual agent channel, AFLAC acquired Zurich North America’s group benefits business in 2020 to enter the “True Group” market (employer-paid life and disability).

• The Competition: This move placed AFLAC in direct competition with established titans like Unum (UNM), The Hartford, and MetLife. These competitors have deep broker relationships and integrated backend systems that AFLAC is still building.
• Margin Dilution: Group insurance is a commodity business with lower margins than voluntary supplemental insurance. Brokers control the distribution and demand high commissions. As AFLAC shifts its mix toward Group Life and Disability, its aggregate U.S. profit margin (currently ~20-21% ¹²) faces compression risk.

3.3 Dental and Vision: A Necessary Defensive Play

AFLAC acquired Argus Dental and Vision to bolster its “network dental” offerings.

• Strategic Imperative: Employers increasingly demand a single provider for all non-medical benefits. If AFLAC cannot offer dental/vision alongside accident/cancer, it risks being excluded from the benefits enrollment platform entirely.
• Operational Friction: Integrating a dental network is complex. In Q3 2025, management noted “softer sales of network dental” ¹⁴, indicating that this growth vector is not yet firing on all cylinders. The transition from a pure indemnity carrier (paying cash) to a network provider (managing provider claims) introduces operational risks and expense drag.

IV. Financial Performance: Deconstructing the Returns

AFLAC’s headline numbers often mask underlying trends due to the volatility of investment gains and currency translation. A forensic approach is required to assess true operating performance.

4.1 Earnings Quality and the “Adjusted” Reality

In Q3 2025, AFLAC reported net earnings of $1.6 billion ($3.08 per share).¹³ However, this figure includes volatile investment gains. The more relevant metric, Adjusted Earnings, was $1.3 billion ($2.49 per share).¹³

• The “Beat” Mechanism: AFLAC frequently beats analyst estimates. In Q3 2025, the beat was driven significantly by reserve remeasurement gains of $580 million.¹⁵ These gains arise when the company updates its actuarial assumptions (e.g., assuming fewer claims or higher terminations). While management argues this reflects conservative past reserving, consistent reserve releases can artificially smooth earnings and boost margins in the short term. Excluding these releases, the underlying underwriting margin would be significantly lower.
• The Buyback Boost: A substantial portion of EPS growth is engineered through share repurchases. In Q3 2025 alone, AFLAC repurchased $1.0 billion of stock, reducing the share count.³ Over time, this mechanical reduction in the denominator (shares outstanding) accounts for a large fraction of the reported EPS growth, obscuring the fact that aggregate Net Income is growing much more slowly (or declining in USD terms due to the weak Yen).

4.2 Return on Equity (ROE) vs. Return on Invested Capital (ROIC)

AFLAC touts a robust Adjusted ROE of 22.1% (excluding FX).¹⁵ However, independent calculations of ROIC tell a different story.

• The Discrepancy: While ROE is high due to the equity base being shrunk by buybacks and AOCI losses (unrealized bond losses), ROIC is often calculated in the 8-11% range.¹⁶
• Implication: This divergence signals that the company is efficient at returning capital but not necessarily at deploying new capital at high rates of return. It confirms the thesis that AFLAC is a mature “cash cow” rather than a high-growth compounder.

4.3 Cash Flow and Capital Deployment

The company generates robust operating cash flow, but the use of that cash is telling.

• Capital Return Dominance: In Q3 2025, AFLAC returned $1.3 billion to shareholders (dividends + buybacks).³ This exceeds the quarter’s adjusted earnings of $1.3 billion, implying a payout ratio of essentially 100% of operating earnings.
• Signaling: When a company returns 100% of its earnings to shareholders, it is implicitly signaling that it lacks high-return internal investment opportunities. Management has effectively decided that buying back its own stock is a better use of capital than aggressively expanding the business organically.

V. Investment Portfolio: The Hidden Risks

AFLAC manages an investment portfolio exceeding $100 billion. In an era of economic uncertainty, the asset side of the balance sheet presents significant risks.

5.1 The Shift to Private Credit and Middle Market Loans

To hunt for yield during the low-interest-rate decade, AFLAC aggressively diversified into Middle Market Loans (MML) and private credit.

• Exposure: As of late 2025, the portfolio contains significant exposure to loans made to companies with EBITDA between $10 million and $50 million.¹⁷
• The Risk: These smaller borrowers are highly sensitive to interest rate hikes (floating rate debt) and economic slowdowns. While AFLAC emphasizes the “senior secured” nature of these loans, in a severe recession, recovery rates on middle-market debt can be poor.
• Tree Line Capital Partnership: AFLAC’s acquisition of a stake in Tree Line Capital Partners ¹⁷ underscores its reliance on third-party originators for this asset class. While this provides access, it also introduces agency risk—the originator is incentivized by volume, while AFLAC bears the credit risk.

5.2 Commercial Real Estate (CRE) Watchlist

AFLAC holds a portfolio of Transitional Real Estate (TRE) loans—effectively bridge loans for properties under renovation or lease-up.

• Office Exposure: A significant portion of this portfolio is in the office sector, which is undergoing a structural crisis in the U.S.
• Rising Reserves: In Q3 2025, AFLAC increased its CECL (Current Expected Credit Losses) reserves for the CRE portfolio by $28 million ¹³, acknowledging deteriorating credit quality. Management has admitted to a “watchlist” of loans approaching foreclosure.⁵
• Foreclosure Reality: The company has already foreclosed on several properties. While management characterizes the exposure as manageable, a deepening CRE crisis could lead to meaningful impairments that would hit book value and earnings.

5.3 Yen Hedging: The Cost of Stability

AFLAC hedges a portion of its Japan exposure to protect its economic solvency ratios (ESR/SMR).

• Cost Drag: With U.S. interest rates significantly higher than Japanese rates, the cost of hedging (selling USD/buying Yen forwards) is high. This creates a persistent drag on net investment income.
• Unhedged Tail Risk: AFLAC leaves a portion of its Japan earnings unhedged. If the Yen were to weaken structurally to 160 or 170 USD/JPY, the USD value of AFLAC’s dividend stream from Japan would be permanently impaired. Conversely, a strengthening Yen (as seen briefly in Q3 2025) provides an accounting tailwind but increases the capital strain on the Japanese subsidiary.

VI. Risk Assessment

6.1 Sovereign and Currency Risk

AFLAC holds tens of billions of dollars in Japanese Government Bonds (JGBs).

• The Scenario: If Japan’s debt-to-GDP load (the highest in the developed world) ever triggers a sovereign debt crisis or a spike in JGB yields, the mark-to-market losses on AFLAC’s balance sheet would be catastrophic. While JGBs are considered “risk-free,” the sheer concentration of AFLAC’s capital in this single asset class represents a massive, unhedged tail risk.

6.2 The Cybersecurity Threat

In June 2025, AFLAC suffered a significant data breach affecting over 22 million individuals, linked to a vulnerability in a file transfer server.¹⁸

• Impact: While operations were not paralyzed by ransomware, the theft of sensitive medical and personal data exposes AFLAC to class-action lawsuits, regulatory fines, and reputational damage. In the insurance business, trust is the product. A breach of this magnitude erodes that trust, particularly in the U.S. market where consumers are increasingly sensitive to data privacy.

6.3 Regulatory Risk in Japan

The Japanese Financial Services Agency (FSA) is a powerful and sometimes unpredictable regulator.

• Pricing Controls: The government essentially controls the pricing of medical services and drugs. If the government expands National Health Insurance (NHI) coverage to include treatments currently covered by private cancer insurance, AFLAC’s product utility vanishes overnight. Conversely, if they cut NHI coverage, AFLAC benefits—but the political winds are fickle.
• Scandal Fallout: The FSA has shown a willingness to punish insurers for the sins of their distributors (as seen in the Japan Post case). Future regulatory actions could restrict AFLAC’s ability to sell through specific channels or mandate changes to commission structures that hurt profitability.

VII. Financial Data & Comparative Analysis

The following tables summarize key financial metrics and comparisons derived from the research material.

Table 1: AFLAC Quarterly Performance Trends (2024-2025)

Metric	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Total Revenue ($B)	$2.95	$5.40	$3.40	$4.20	$4.74
Adj. Earnings ($B)	$1.20	$0.87	$0.91	$0.96	$1.30
Adj. EPS ($)	$1.84	$1.56	$1.66	$1.78	$2.49
Net Earnings ($B)	($0.09)	$1.90	$0.03	$0.60	$1.60
Japan Sales Growth (YoY)	—	+9.0%	+12.6%	+23.2%	+11.8%
U.S. Sales Growth (YoY)	—	-1.0%	+3.5%	+2.7%	+2.8%

Source: Aggregated from Earnings Reports ¹²

Analysis:

• Revenue Volatility: The wild swings in Total Revenue (from $5.4B down to $3.4B and back to $4.7B) are driven by investment gains/losses and currency effects, obscuring the stability of the underlying insurance business.
• Sales Trends: Japan sales spiked in Q2 2025 (+23.2%) due to the launch of Miraito, but normalized to +11.8% in Q3. U.S. sales growth remains anemic (low single digits), barely matching inflation.

Table 2: Peer Valuation Comparison (Late 2025)

Company	Ticker	P/E Ratio (TTM)	P/B Ratio	Div Yield	Revenue Growth (TTM)
Aflac	AFL	~14.4x	~2.0x	2.2%	+2.3%
Unum Group	UNM	~15.3x	~1.0x	~3.0%	+4.7%
MetLife	MET	~13.8x	~1.3x	~3.1%	+2.1%
Prudential	PRU	~18.2x	~0.9x	~4.5%	+8.0%

Source: Derived from ¹⁹

Analysis:

• Premium Valuation: AFLAC trades at a significant premium to Book Value (2.0x) compared to its peers (0.9x – 1.3x). The market awards this premium for AFLAC’s perceived safety and the absence of “toxic” Long-Term Care liabilities that plague Unum.
• Growth Disconnect: Despite the premium valuation, AFLAC’s revenue growth is lower than Prudential and Unum. Investors are paying a high price for “quality” and “capital return” rather than growth.

VIII. Conclusion and Investment Verdict

8.1 The Thesis: A Mature Cash Machine, Not a Growth Engine

AFLAC Inc. is not a growth company. It is a highly efficient machine for extracting capital from a mature, saturated market (Japan) and returning it to shareholders. The “growth story” sold by management—centered on U.S. expansion and new products like Miraito—is secondary to the financial engineering story driven by share buybacks.

8.2 Strengths

• Capital Discipline: Management’s commitment to the dividend (43 years of increases) and buybacks is unwavering.
• Japan Margins: Despite headwinds, the Japan business generates exceptional pretax margins (38.5% in Q3 2025 ¹⁴), far superior to most insurance lines.
• Liability Profile: AFLAC lacks the long-tail liability risks (asbestos, LTC) that haunt other insurers.

8.3 Weaknesses and Risks

• Japan Concentration: The company is effectively a proxy for the Japanese economy and demographics. The shrinking population is a mathematical ceiling on long-term organic growth.
• Distribution Fragility: The Japan Post scandals prove that AFLAC’s distribution moat is vulnerable to partner misconduct.
• Asset Quality: Rising exposure to private credit and CRE loans introduces credit risk that could surprise investors in a recession.

8.4 Final Verdict: HOLD

At a valuation of ~2.0x Book Value and ~14.4x Earnings, AFLAC is priced for perfection. The current price reflects its quality but offers no margin of safety for the structural risks in Japan or the potential credit cycle turn in the U.S.

• For Income Investors: The 2.2% yield is safe but unexciting compared to alternatives in the sector offering 3-4%.
• For Growth Investors: There is little organic growth to be found here.
• For Conservative Capital Preservation: AFLAC remains a solid “Hold.” It is a defensive stock that will likely outperform in a mild downturn but lag in a roaring bull market or a severe credit crisis.

Strategic Recommendation: Investors should monitor the Japan Post relationship closely for any signs of further strain. Additionally, the performance of the CRE loan watchlist in upcoming quarters will be a bellwether for the health of the investment portfolio. Any spike in non-accruals there would be a signal to exit. Conversely, a significant pullback in the stock price (e.g., to ~1.3x Book Value) would make the share buyback math highly accretive and present a buying opportunity.

Frequently Asked Questions

General Questions

• What thoughtful questions have other investors asked about this company? Investors are currently focused on whether the “moat” in Japan is eroding due to the recurrence of scandals at its key partner, Japan Post, and whether the U.S. segment can generate enough organic growth to offset a mature Japanese market. Critical questions include:
  1. Is the 2025 data breach affecting 22 million U.S. customers a one-off event or a sign of systemic operational weakness?
  2. Can Aflac maintain its premium valuation (approx. 2x Book Value) if sales growth in Japan remains tied to low-margin savings products like Tsumitasu rather than high-margin cancer policies?
  3. Does the rising exposure to private credit and commercial real estate (CRE) in the investment portfolio pose a threat to book value in a “higher-for-longer” rate environment?

Cyclicality & Earnings Nature

• Are earnings at a cyclical high or cyclical low? Earnings are likely near a cyclical high, artificially boosted by a weak Yen (which helps capital ratios but hurts reported USD earnings) and aggressive share buybacks. The company reported net earnings of $5.4 billion for 2024, a 16.7% increase, largely driven by investment gains and reserve releases rather than core underwriting growth.
• Are earnings driven primarily by the external environment or internal company actions? Currently, they are driven heavily by external factors (Yen/USD exchange rates and investment yields) and financial engineering (buybacks). While internal actions like the Miraito product launch in Japan have helped sales, the bottom-line growth per share is heavily supported by reducing the share count.
• How stable are revenues? Revenues are volatile in USD terms due to currency translation. For the first nine months of 2025, total revenues declined 9.1% to $12.3 billion, largely due to the weak Yen and investment losses. Underlying insurance revenues in Yen are stable but stagnant.
• Outlook for the company’s products and services? The outlook is mixed. In Japan, demand for “third sector” (cancer/medical) insurance remains, but Aflac is shifting toward lower-margin “first sector” (savings/asset formation) products like Tsumitasu to generate volume. In the U.S., the company is pivoting to “Group Benefits” (dental/vision/disability) to find growth, entering a commoditized market with lower margins than its core supplemental business.

Business Quality & Competitive Moat

• Is the industry getting more or less competitive? Significantly more competitive. In Japan, deregulation has allowed domestic giants like Nippon Life to aggressively enter Aflac’s niche cancer insurance market. In the U.S., the voluntary benefits space is crowded with players like Unum and MetLife aggressively competing on price.
• How profitable is this business? It remains highly profitable, but margins are under pressure. Aflac’s ROE for Q3 2025 was 22.1% (excluding currency impacts), which is superior to peers like Unum (~13% ROE) and MetLife. However, the Japan pretax profit margin, historically over 30%, is threatened by the mix shift to lower-margin savings products.
• What are the barriers to entry? The primary barrier is the massive scale of data Aflac possesses on cancer claims in Japan (50 years of data), allowing for precise underwriting. However, brand and distribution barriers are eroding; the Japan Post channel has been compromised by repeated scandals.
• Do brands matter? Yes, the “Aflac Duck” has created 90%+ brand recognition in both the U.S. and Japan. This provides a “door opener” for agents, but it does not grant unlimited pricing power in a commoditized market.

Financial Condition & Balance Sheet

• Does the company have assets that are not fully recognized in the balance sheet? Aflac holds a massive portfolio of Japanese Government Bonds (JGBs) classified as “Held-to-Maturity” or “Available-for-Sale.” Rising interest rates in Japan could create unrealized losses on these bonds that do not flow through the income statement but would impact Book Value if marked to market.  
• What off-balance sheet liabilities does the company have? Aflac uses “Pre-Capitalized Trust Securities” (P-Caps) as contingent financing. In August 2025, Aflac entered into $2 billion of these arrangements, which are off-balance sheet until drawn upon.  
• How conservative is the company’s accounting? Aflac frequently releases reserves (e.g., $580 million in Q3 2025), which boosts earnings. While management claims this proves past conservatism, consistent large releases can be a way to smooth earnings volatility and mask underlying underwriting deterioration.
• Does the company have “hidden” asset risks? Yes. The investment portfolio has shifted toward higher risk. As of late 2024/2025, Aflac holds substantial exposure to “Middle Market Loans” ($4.3 billion) and “Transitional Real Estate” ($4.7 billion), sectors highly vulnerable to economic downturns. The company foreclosed on several properties in 2024.

Capital Allocation & Management

• How much free cash flow does the business generate? Aflac generated approximately $2.7 billion in free cash flow in 2024, though this was a decline from previous years.
• How does management use this free cash flow? The priority is returning capital to shareholders. In Q3 2025 alone, Aflac returned $1.3 billion to shareholders via dividends and buybacks. This payout ratio often exceeds 100% of reported earnings, signaling a liquidation mode rather than reinvestment for growth.
• Has the company made any significant acquisitions recently? Aflac acquired a 40% stake in Tree Line Capital Partners in May 2024 to expand its exposure to private credit and direct lending. This move indicates a chase for yield to support investment income.  
• Is the company buying back shares? Aggressively. Aflac repurchased $1.0 billion in shares in Q3 2025 and has authorization to purchase up to 100 million more shares.
• What are the motivations of management? CEO Daniel Amos has been in charge since 1990 and received $19.27 million in total compensation in 2024. Compensation is heavily tied to stock performance and ROE, incentivizing buybacks over organic growth investments.

Valuation & Market Data

• Dividend Policy? Aflac is a “Dividend Aristocrat” with 43 consecutive years of increases. The current yield is approximately 2.2%, with a payout ratio of around 30%.
• How profitable is this business? Net profit margins are robust at ~23.6% , significantly higher than the industry average, largely due to the historically high margins of the legacy cancer book in Japan.
• Is the stock an ADR? No, AFL is the primary ticker listed on the NYSE. It is a U.S. corporation, not an ADR.

Risks & Downside

• What factors would cause the stock to decline?
  1. Japan Post Scandal: Reports in 2025 indicate that up to 10 million customer accounts were misused, a massive escalation from previous scandals. This could lead to severe regulatory punishment or a suspension of sales.
  2. Currency: A structural collapse of the Yen below 160/USD would permanently impair the USD value of Aflac’s Japanese earnings.
  3. Credit Cycle: A recession triggering defaults in its middle-market loan portfolio or commercial real estate holdings.
• What is the risk of a catastrophic loss? Cybersecurity. In June 2025, Aflac suffered a massive data breach affecting over 22 million individuals. The class-action lawsuits and potential regulatory fines from this event represent a significant, unquantified liability.

Recent News & Events

• Has the business environment changed recently? Yes. The recurrence of the Japan Post scandal in 2025 and the massive U.S. data breach in June 2025 have materially increased the operational and reputational risk profile of the company.
• Recent changes in the business? Aflac Japan launched Miraito (cancer insurance) and Tsumitasu (savings/nursing care) in 2024/2025 to revive flagging sales. While sales numbers are up, the quality of these sales (lower margin savings products) is lower than the historical book.

Works cited

1. Aflac NPS 2025, accessed December 26, 2025, https://s24.q4cdn.com/367535798/files/doc_financials/2025/ar/436109-3-_29_Aflac_NPS_Workiva_WR-2.pdf
2. Aflac | AFL Stock Price, Company Overview & News – Forbes, accessed December 26, 2025, https://www.forbes.com/companies/aflac/
3. Aflac Incorporated Announces Third Quarter Results, Reports Third …, accessed December 26, 2025, https://investors.aflac.com/press-releases/press-release-details/2025/Aflac-Incorporated-Announces-Third-Quarter-Results-Reports-Third-Quarter-Net-Earnings-of-1-6-Billion-Declares-Fourth-Quarter-Dividend/default.aspx
4. Aflac Incorporated : Fourth Quarter 2024 Investment Details – Finnhub, accessed December 26, 2025, https://finnhub.io/api/news?id=c2637ce8d706167cf5c0329e4723f3ece7241c427baf626aa0663141b127571d
5. Aflac shares rise as execs quell concerns over commercial …, accessed December 26, 2025, https://www.spglobal.com/market-intelligence/en/news-insights/articles/2023/4/aflac-shares-rise-as-execs-quell-concerns-over-commercial-mortgage-pressure-75417232
6. AFLAC INC SEC 10-K Report — TradingView News, accessed December 26, 2025, https://www.tradingview.com/news/tradingview:d7f04b1ec44e2:0-aflac-inc-sec-10-k-report/
7. Aflac Incorporated Debt Update August 2025, accessed December 26, 2025, https://s24.q4cdn.com/367535798/files/doc_presentations/2025/Aug/19/Debt-Investor-Update-Aug-2025.pdf
8. Japan Post irregularly sold 104,000 Aflac policies – report, accessed December 26, 2025, https://www.insurancebusinessmag.com/asia/news/breaking-news/japan-post-irregularly-sold-104000-aflac-policies–report-175926.aspx
9. Number of Japan Post clients affected by misuse of information rises …, accessed December 26, 2025, https://www.japantimes.co.jp/news/2025/03/18/japan/japan-post-customer-information-misappropriate/
10. Japan Post insurance arm embroiled in data misuse controversy …, accessed December 26, 2025, https://reinasia.com/japan-post-insurance-arm-embroiled-in-data-misuse-controversy-affecting-10-million-customer-accounts/
11. Aflac Incorporated Announces First Quarter Results, Reports First …, accessed December 26, 2025, https://investors.aflac.com/press-releases/press-release-details/2025/Aflac-Incorporated-Announces-First-Quarter-Results-Reports-First-Quarter-Net-Earnings-of-29-Million-Declares-Second-Quarter-Dividend/default.aspx
12. Aflac Inc Earnings – Analysis & Highlights for Q3 2025 – AlphaSense, accessed December 26, 2025, https://www.alpha-sense.com/earnings/afl/
13. Earnings call transcript: Aflac’s Q3 2025 earnings soar past …, accessed December 26, 2025, https://www.investing.com/news/transcripts/earnings-call-transcript-aflacs-q3-2025-earnings-soar-past-expectations-93CH-4333784
14. Aflac Incorporated Announces Fourth Quarter Results, Reports …, accessed December 26, 2025, https://investors.aflac.com/press-releases/press-release-details/2025/Aflac-Incorporated-Announces-Fourth-Quarter-Results-Reports-Fourth-Quarter-Net-Earnings-of-1.9-Billion-Reiterates-Increase-in-First-Quarter-Dividend-of-16/default.aspx
15. Aflac Incorporated (AFL) Q3 2025 Earnings Call Transcript, accessed December 26, 2025, https://seekingalpha.com/article/4838263-aflac-incorporated-afl-q3-2025-earnings-call-transcript
16. Return on Invested Capital For Aflac Inc (AFL) – Finbox, accessed December 26, 2025, https://finbox.com/NYSE:AFL/explorer/roic/
17. Aflac Global Investments to acquire stake in private credit asset …, accessed December 26, 2025, https://investors.aflac.com/press-releases/press-release-details/2024/Aflac-Global-Investments-to-acquire-stake-in-private-credit-asset-management-firm-Tree-Line-Capital-Partners/default.aspx
18. Aflac breach exposes personal and health data of more than 22M …, accessed December 26, 2025, https://siliconangle.com/2025/12/24/aflac-breach-exposes-personal-health-data-22m-people/
19. Aflac Incorporated – ROE – Wisesheets, accessed December 26, 2025, https://www.wisesheets.io/roe/0H68.L
20. Aflac (AFL) Dividend History, Dates & Yield – Stock Analysis, accessed December 26, 2025, https://stockanalysis.com/stocks/afl/dividend/
21. Aflac (AFL) Stock Forecast and Price Target 2025 – MarketBeat, accessed December 26, 2025, https://www.marketbeat.com/stocks/NYSE/AFL/forecast/
22. Aflac Vs Unum: Which is a Better Buy? AI Stock Analysis – Danelfin, accessed December 26, 2025, https://danelfin.com/stocks/AFL-aflac-vs-UNM-unum-compare